COVID-19 and Fungal infections: a double debacle |
| |
| Institution: | 1. Department of Medical Laboratory Sciences, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon;2. Univ Angers, Univ Brest, IRF, SFR ICAT, F-49000, Angers, France;3. Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital of Angers, Angers, France;4. Univ Angers, Université de Nantes, LPPL, SFR CONFLUENCES, F-49000 Angers, France;5. Univ Angers, Université de Nantes, Inserm, CRCINA, INCIT, SFR ICAT, F-49000 Angers, France;6. Infectious Diseases Department, Angers University Hospital, Angers, France |
| |
| Abstract: | Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal infections constitutes a double debacle for patients, healthcare experts, and the public economy. Since the first appearance of SARS-CoV-2, a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present review attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients: Aspergillus, Candida, and Mucorales species. |
| |
| Keywords: | Fungal infections COVID-19 Mucoromycetes |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
